Cyclodextrins in Biopharma on June 21, 2023

This free webinar series explores the present and future applications of cyclodextrins in biopharma through a series of educative sessions. It focuses on cyclodextrin uses in protein formulations (monoclonal antibodies), gene therapy, vaccines, and other biotech applications. The webinar includes an overview of the current market, three concise lectures by experts from Roquette and CarboHyde, and concludes with a moderated panel discussion featuring the speakers and key opinion leaders.

The audience can ask questions and participate in an open discussion about the challenges and possibilities of these innovative applications.

You can register here: Cyclodextrin in Biopharma (and more details about the program and experts)


  • BioPharma Market Insights (15 min)
    Elham Blouet, Regional Head Bio Pharma Technology, Roquette
  • Revolutionizing Gene Therapy: The Dynamic Duo of Cyclodextrins and Gene Delivery (40 min*)
    Milo Malanga, CarboHyde
  • Unlock the potential of KLEPTOSE® Hydroxypropyl beta-cyclodextrin in biologics downstream process and formulation development (40 min*)
    Peng Tao, BioPharma Research Manager, Roquette
  • Polysorbates versus KLEPTOSE® HPB Hydroxypropyl Beta-Cyclodextrin: Comparative Study on Stability & Antibody Stabilization (40  min*)
    Hailong Zhang, Research Analytical Manager, Roquette
  • Panel discussion (45 min): Cyclodextrins-based formulations in Biopharma – current and future applications, advantages, and challenges

See more details here: Webinar: Cyclodextrins in Biopharma | Roquette

Antimony and naphthalene can be simultaneously leached from a combined contaminated soil using carboxymethyl-β-cyclodextrin as a biodegradable eluant

today’s cyclodextrin:
The use of CDs in soil remediation has a long history. Here is the most recent chapter.
The removal efficiency of antimony (Sb) and naphthalene (Nap) from a combined contaminated soil was studied by carboxymethyl-β-cyclodextrin (CMCD) leaching and reveal its remediation mechanisms. The results show that the highest removal efficiencies of Sb and Nap were 94.82% and 93.59%, respectively. The breakthrough curves show that CMCD had a stronger inclusion capacity of Nap than Sb, and Sb could enhance the adsorption capacity of Nap, while Nap weakened the adsorption of Sb during CMCD leaching. CMCD is a good eluant for remediating soil contaminated by a combination of heavy metals and polycyclic aromatic hydrocarbons (PAHs), and its remediation mechanisms depend on the complexation reactions between the surface functional groups and inclusion reactions in the internal cavities.

See the full article here

University of Sydney and CarboHyde join forces in groundbreaking collaboration to combat natural toxins

University of Sydney, a leading innovator in researching natural toxins and poisons, and CarboHyde, a renowned expert in developing therapeutic carbohydrates are proud to announce their strategic partnership in the fight against natural toxins. This groundbreaking collaboration aims to advance research, develop effective solutions, and raise awareness about the detrimental impact of natural toxins on human health.

The world faces a growing threat from natural toxins, which can be found in various forms, including harmful algal blooms, venomous organisms, and poisonous plants. These toxins pose significant challenges to public health, wildlife, and ecosystems, demanding immediate attention and collaborative efforts to mitigate their harmful effects.

By combining their unique expertise, University of Sydney, led by Greg Neely and CarboHyde will work hand in hand to develop innovative technologies and approaches for neutralizing natural toxins and developing antidotes against poisoning or for prevention. “Our joint efforts will not only enhance the scientific understanding of these toxins but also pave the way for effective preventive measures and responsive strategies” – said Joseph Toth, CEO of CarboHyde. “Natural toxins present a complex and multifaceted challenge, requiring interdisciplinary solutions. This collaboration allows us to leverage our respective strengths and resources to address this pressing issue collaboratively. Together, we aim to develop comprehensive strategies that safeguard public health.” he added. 

The partnership between the University of Sydney and CarboHyde signifies a milestone in the fight against natural toxins. By combining their research capabilities, technical expertise, and industry knowledge, these two partners are committed to making significant contributions to toxin detection, risk assessment, and effective mitigation strategies.

Nanotechnology-based eye treatment

today’s cyclodextrin:
It was announced that one of the patents from Thorsteinn Loftsson and Einar Stefansson (EP1909755B1 Cyclodextrin Nanotechnology for Ophthalmic Drug Delivery) had been selected as one of the three finalists for the European Inventor Award 2023. The three were selected out of 600 nominations. This technology laid the foundation of Oculis (
The European Inventor Award is a global, highly recognized innovation prize that celebrates the “Tomorrow Shapers” – inventors whose perseverance, ingenuity, and creativity are paving the way to a brighter future. Since 2013 the public has been invited to vote while keeping a scientific jury to judge proposals.

You can vote for your favorite inventors here:  European Inventor Award

InnoGly COST Action Closing meeting

Tamas Sohajda represented us at the closing meeting of InnoGly a European COST Action aimed at facilitating networking and innovation of glycans in the field of cancer research, autophagy, immunity, and glycosaminoglycans. This was a fantastic experience and the start of several useful collaborations for the future.

Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation

A very recent patent application from ASDERA on using hyproxypropyl-alfa-cyclodextrin formulated with a medium chain fatty acid (ideally a cproic acid derivative) for the ORAL delivery is the CD. Similarly to our interests, the CD itself is proposed to be the therapeutic agent and the oral delivery would open a new solution to treat cancer or a neurodegenerative, cardiovascular, metabolic, inflammatory, autoimmune, age-related, or viral disease or disorder in a subject which is currently only possible via parenteral administration. Keep an eye on Knut M. Wittkowski as his research is highly important. Overcoming the current issues with CD dosing is an unsolved problem in this research area.

See the full patent here: Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation

Surface Modification of Bi2O3 Nanoparticles with Biotinylated β-Cyclodextrin as a Biocompatible Therapeutic Agent for Anticancer and Antimicrobial Applications

Just because we think functionalizing cyclodextrin with biotin is fancy and could have a great variety of uses.
This paper describes a new route to the surface modification of bismuth oxide nanoparticles (Bi2O3 NPs) using functionalized beta-Cyclodextrin (β-CD) as a biocompatible system. The synthesis of Bi2O3 NP was done using PVA (polyvinyl alcohol) as the reductant and the Steglich esterification procedure for the functionalization of β-CD with biotin. Ultimately, the Bi2O3 NPs are modified using this functionalized β-CD system. The antibacterial and anticancer effects of the surface-modified Bi2O3 NP system were also investigated.
Jogy Alex and Thomas Mathew

See the full article here: Surface Modification of Bi2O3 Nanoparticles with Biotinylated β-Cyclodextrin as a Biocompatible Therapeutic Agent for Anticancer and Antimicrobial Applications